Our in vivo studies show anti-fibrotic effects of VEGFR2 inhibition in experimental kidney fibrosis, suggesting that the Gremlin/VEGFR2 axis could be a potential therapeutic target in renal disease. Here, GREM1 is linked to kidney disorder.